Passage Bio Appoints Sandip Kapadia to Board of DirectorsHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 16 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Passage Bio Appoints Sandip Kapadia to Board of DirectorsGlobeNewswireJanuary 10, 2020ReblogShareTweetSharePHILADELPHIA, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced the appointment of Sandip Kapadia to its board of directors. Mr. Kapadia is currently the chief financial officer and treasurer of Intercept Pharmaceuticals.“Sandip brings over 20 years of financial expertise and will be an invaluable asset to our board of directors and rapidly advancing organization. We look forward to drawing from his experience in building and leading finance and administration teams at life sciences companies worldwide,” said Dr. Stephen Squinto, co-founder and interim chief executive officer at Passage Bio.Sandip Kapadia, MBA, CPA, has served as the chief financial officer of Intercept Pharmaceuticals, Inc. since July 2016. Prior to joining Intercept, Mr. Kapadia served in various leadership capacities within finance over 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the U.S. Mr. Kapadia received a B.S. in Accounting from Montclair State University and an M.B.A. from Rutgers University, and is also a U.S. Certified Public Accountant.About Passage Bio Passage Bio is a privately-held genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of six product candidates, with the option to license six more, with lead programs in GM1 gangliosidosis, Fronto-Temporal dementia and Krabbe disease. Since inception, Passage Bio has raised $225 million with investments from OrbiMed, Versant Ventures, Frazier Healthcare Partners, Access Biotechnology, Lily Asia Ventures, New Leaf Venture Partners, Vivo Capital, and Boxer Capital of Tavistock Group, among others.For further information, please contact:Investors:Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.comMedia:Emily MaxwellHDMZ312-506-5220emily.maxwell@hdmz.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextIntercept Pharmaceuticals, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To KnowSimply Wall St.Don't Race Out To Buy Novartis AG (VTX:NOVN) Just Because It's Going Ex-DividendSimply Wall St.Intercept (ICPT) Q4 Earnings Miss, Revenues Beat EstimatesZacksSandoz to keep prices stable on coronavirus-relevant drugsReutersMerck Stock Is Forming A Flat Base — But Is It Time To Take On Shares?Investor's Business DailyBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoWhat the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoLoan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance Video